{
    "Trade/Device Name(s)": [
        "Wondfo Methamphetamine Urine Test (MET 300)",
        "Wondfo Oxazepam Urine Test (BZO 200)"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K132630",
    "Predicate Device Reference 510(k) Number(s)": [
        "K050394"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJC",
        "JXM"
    ],
    "Summary Letter Date": "September 27, 2013",
    "Summary Letter Received Date": "August 22, 2013",
    "Submission Date": "August 11, 2013",
    "Regulation Number(s)": [
        "21 CFR 862.3610",
        "21 CFR 862.3170"
    ],
    "Regulation Name(s)": [
        "Methamphetamine test system",
        "Benzodiazepine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "D(+)-Methamphetamine",
        "Oxazepam"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Dip Card",
        "Cup"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow",
        "Competitive binding"
    ],
    "Methodologies": [
        "Antigen-antibody immunochemistry",
        "Qualitative detection"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Wondfo Methamphetamine and Oxazepam urine tests using lateral flow immunochromatographic assay for qualitative toxicology screening",
    "Indications for Use Summary": "Qualitative determination of D(+)-Methamphetamine (MET 300, cutoff 300 ng/mL) or Oxazepam (BZO 200, cutoff 200 ng/mL) in human urine; preliminary prescription-only test, not for point-of-care use, requiring confirmatory GC/MS for positive results",
    "fda_folder": "Toxicology"
}